I was reading through the various links regarding top line results provided by BDAZ and I find the Norvartis release interesting and perhaps a good sign for apabetalone.

Source – BDAZ – link in July 13, 2018, 12:09 p.m. post.

Novartis.

ACZ885 is the first and only investigational agent which has shown that selectively targeting inflammation reduces cardiovascular risk.

Despite standard treatment, people with a prior heart attack live with a higher ongoing risk of having another event or dying, and it has been shown that in about four in 10 people, this risk is directly related to increased inflammation associated with atherosclerosis[1].

***********

My comment - One of the impacts of apabetalone is reducing inflammation along with numerous other benefits that we are all aware of. On the surface it seems like good news that for RVX that Novartis has shown positive evidence toward the inflammation hypothesis.

GLTA

Toinv